ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. The company's lead product, Nuplazid (pimavanserin), is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's pipeline includes product candidates for the treatment of schizophrenia, dementia-related psychosis, and major depressive disorder. The company was founded in 1993 and is headquartered in San Diego, California.